| 主权项 |
1. A method for obtaining a prognosis for a cancer patient upon treatment with a proteasome inhibitor comprising:
a) determining the amount of a marker or a plurality of markers in a patient sample comprising hematological tumor cells; b) comparing the amount of the marker or plurality of markers to a control amount to determine whether the amount of the marker or markers is informative; and c) determining the prognosis of treatment with the proteasome inhibitor if the amount of the marker in the patient sample is informative,wherein the prognosis is selected from the group consisting of short term survival, long term survival, good response, poor response, short time-to-progression and long time-to-progression;wherein the marker is a gene or a plurality of genes on a chromosome locus or chromosome loci selected from the group consisting of chromosome 8p from base pair 14545026 to 18399369, chromosome 8p from base pair 23814813 to 30588991, chromosome 11q from base pair 99227505 to 103705782, chromosome 1p from base pair 2266413 to 14000056, chromosome 1p from base pair 19701552 to 29298088, chromosome 1p from base pair 77343211 to 85282786, chromosome 1p from base pair 86923961 to 94919204, chromosome 2p from base pair 1364596 to 20869183, chromosome 2p from base pair 25587346 to 48499848, chromosome 2p from base pair 53374467 to 56347145, chromosome 2p from base pair 60321030 to 62325264, and chromosome 2p from base pair 68972513 to 77035713. |
